Trial Profile
Study of neuroendocrine differenciation of prostate cancer and the outcomes of everolimus against neuroendocrine prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Mar 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
- 21 May 2018 Results (n=11) of pathologically proven neuroendocrine prostate cancer patients presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 New trial record